Literature DB >> 9779169

CSF antibiotic prophylaxis for neurosurgical patients with ventriculostomy: a randomised study.

W S Poon1, S Ng, S Wai.   

Abstract

The value of prophylactic antibiotics for patients with ventricular catheter for monitoring and CSF drainage is uncertain. 228 patients were randomised to receive perioperative antibiotics only (Unasyn, Group I) or prolonged antibiotics for the presence of the ventricular catheter (Unasyn and Aztreonam, Group II). The incidence of intracranial and extracranial infection was documented prospectively. Group II patients had a significantly reduced incidence of CSF infection [3/115 (3%) vs 12/113 (11%), p = 0.01] and extracranial infections [23/115 (20%) vs 48/113 (42%), p = 0.002]. CSF pathogens in Group II patients were MRSA and Candida, whereas in Group I, Staphylococci, E coli and Klebsiella. Although prolonged antibiotic prophylaxis significantly reduced the incidence of serious CSF infection as well as extracranial infections, this policy did select resistant or opportunistic pathogens such as Candida and MRSA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9779169     DOI: 10.1007/978-3-7091-6475-4_43

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  25 in total

1.  Variations in Strategies to Prevent Ventriculostomy-Related Infections: A Practice Survey.

Authors:  Ariane Lewis; Barry M Czeisler; Aaron S Lord
Journal:  Neurohospitalist       Date:  2016-08-11

2.  International and specialty trends in the use of prophylactic antibiotics to prevent infectious complications after insertion of external ventricular drainage devices.

Authors:  Paul J McCarthy; Shashikant Patil; Steven A Conrad; L Keith Scott
Journal:  Neurocrit Care       Date:  2010-04       Impact factor: 3.210

3.  Risk of Resistant Organisms and Clostridium difficile with Prolonged Systemic Antibiotic Prophylaxis for Central Nervous System Devices.

Authors:  Stephanie Chauv; Gabriel V Fontaine; Quang P Hoang; Courtney B McKinney; Margaret Baldwin; Whitney R Buckel; Dave S Collingridge; Sarah Majercik; Paul D Wohlt
Journal:  Neurocrit Care       Date:  2016-08       Impact factor: 3.210

4.  Continuous antibiotic prophylaxis and cerebral spinal fluid infection in patients with intracranial pressure monitors.

Authors:  John J Flibotte; Kim En Lee; Walter J Koroshetz; Jonathan Rosand; Colin T McDonald
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

5.  Effect of a bundle approach on external ventricular drain-related infection.

Authors:  Bujung Hong; Anani Apedjinou; Hans E Heissler; Hind Chaib; Josef M Lang; Shadi Al-Afif; Joachim K Krauss
Journal:  Acta Neurochir (Wien)       Date:  2021-01-11       Impact factor: 2.216

6.  Risk factors associated with infections and need for permanent cerebrospinal fluid diversion in pediatric intensive care patients with externalized ventricular drains.

Authors:  Alexis A Topjian; Amber Stuart; Alyssa A Pabalan; Ashleigh Clair; Todd J Kilbaugh; Nicholas S Abend; Robert A Berg; Gregory G Heuer; Phillip B Storm; Jimmy W Huh; Stuart H Friess
Journal:  Neurocrit Care       Date:  2014-10       Impact factor: 3.210

Review 7.  Nosocomial infections in neurocritical care.

Authors:  Rafael Ortiz; Kiwon Lee
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

Review 8.  The Insertion and Management of External Ventricular Drains: An Evidence-Based Consensus Statement : A Statement for Healthcare Professionals from the Neurocritical Care Society.

Authors:  Herbert I Fried; Barnett R Nathan; A Shaun Rowe; Joseph M Zabramski; Norberto Andaluz; Adarsh Bhimraj; Mary McKenna Guanci; David B Seder; Jeffrey M Singh
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

9.  Evaluation of mannitol as an osmotherapeutic agent in traumatic brain injuries by measuring serum osmolality.

Authors:  R M Sharma; R Setlur; M N Swamy
Journal:  Med J Armed Forces India       Date:  2011-08-07

10.  Intensive care unit management of patients with stroke.

Authors:  Sebastian Schulz-Stübner
Journal:  Curr Treat Options Neurol       Date:  2007-11       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.